Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Danaher Corporation (DHR)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
258.29-3.86 (-1.47%)
At close: 04:04PM EDT
259.00 +0.71 (+0.27%)
After hours: 07:44PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close262.15
Open262.14
Bid258.00 x 800
Ask259.20 x 800
Day's Range258.03 - 265.60
52 Week Range233.71 - 331.69
Volume2,667,230
Avg. Volume2,160,201
Market Cap187.892B
Beta (5Y Monthly)0.89
PE Ratio (TTM)30.42
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.00 (0.39%)
Ex-Dividend DateSep 29, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-15% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for DHR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Danaher Corporation
    Analyst Report: Danaher CorporationIn 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.
    Rating
    Fair Value
    Economic Moat
    18 days agoMorningstar
View more
Advertisement
Advertisement